Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | PDE6D | O43924 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552173 | 0.82 | MGLL (0.53) | ALDH1A1HTT | |
| SCHEMBL5870552 | 0.81 | HPGD (0.39) | POLBALDH1A1HTTHSD17B10NR1H2 | |
| SCHEMBL4649466 | 0.76 | POLB (0.65) | POLBALDH1A1NR1H3NR1H2MEN1 | |
| SCHEMBL454828 | 0.71 | POLB (0.51) | POLBALDH1A1HSD17B10NR1H3NR1H2 | |
| SCHEMBL9067222 | 0.71 | MGLL (0.68) | POLBALDH1A1HTTHSD17B10NR1H3 | |
| SCHEMBL10621855 | 0.71 | HDAC4 (0.47) | ALDH1A1HTTHSD17B10NR1H2MEN1 | |
| SCHEMBL11110156 | 0.70 | KMT2A (0.61) | ALDH1A1HSD17B10MEN1KMT2ALMNA | |
| SCHEMBL11860388 | 0.69 | ADORA2A (0.62) | POLBALDH1A1HTTNR1H3NR1H2 | |
| SCHEMBL19888 | 0.68 | MEN1 (0.50) | POLBALDH1A1HTTMEN1KMT2A | |
| SCHEMBL27698994 | 0.68 | POLB (0.44) | POLBALDH1A1HTTHSD17B10NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558255-B1 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NEUROPHARMA SA (ES) | 2006-12-27 | — | — | EP | claimed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20050272649-A1 | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure | STRYKER CORPORATION | 2005-12-08 | — | — | US | disclosed |
| EP-1578360-A2 | CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE | Curis, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004019876-A2 | CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE | CURIS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-4310461-A | HYPTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272649-A1 | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure | BMPR2, BMP2, BMP1 | POLB 4637/4885ALDH1A1 1747/4885HTT 4877/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | POLB 2662/4885ALDH1A1 2614/4885HTT 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.